Related Experiment Video
Updated: May 3, 2026

Detecting Anastasis In Vivo by CaspaseTracker Biosensor
Published on: February 1, 2018
Serum level of tumor marker carbohydrate antigen-CA125 in heart failure
Azra Durak-Nalbantic1, Nerma Resic2, Mehmed Kulic2
1Clinic for Heart disease and rheumatism, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina. azradurak@yahoo.com
Insights
Serum carbohydrate antigen 125 (CA125) is elevated in decompensated heart failure (HF) patients, especially those with effusions. CA125 correlates with brain natriuretic peptide (BNP) and may indicate systemic congestion.
Area of Science:
- Cardiology
- Biomarker Research
- Internal Medicine
Background:
- Heart failure (HF) diagnosis and management rely on clinical assessment and biomarkers.
- Brain natriuretic peptide (BNP) is a key biomarker for HF, but its interpretation can be complex.
- Carbohydrate antigen 125 (CA125) is a tumor marker with potential roles in non-oncological conditions like HF.
Purpose of the Study:
- To evaluate serum CA125 levels in patients with heart failure.
- To explore the correlation between CA125, echocardiographic parameters, and BNP levels in HF patients.
- To determine if CA125 can serve as a marker for systemic congestion in decompensated HF.
Main Methods:
- Inclusion of 76 patients with cardiac symptoms, divided into HF (n=50) and control (n=26) groups.
- Subdivision of HF patients into compensated (compHF) and decompensated (decompHF) groups based on fluid overload.
- Measurement of serum CA125 and BNP, along with ECG and echocardiography, on admission.
Main Results:
- Significantly higher CA125 levels in HF patients compared to controls (71.05 vs 10.75 U/ml).
- Elevated CA125 in decompHF (94.90 U/ml) versus compHF (11.90 U/ml) and further increased in patients with pleural/pericardial effusion (205.10 U/ml).
- Positive correlation between CA125 and BNP (r=0.293, p=0.039); no significant correlation with LVEF or left atrium diameter.
Conclusions:
- Serum CA125 is elevated in decompensated HF, particularly with serosal effusions.
- CA125 levels correlate with BNP, suggesting a role in reflecting systemic congestion and volume overload.
- CA125 may serve as a valuable adjunct marker in assessing decompensated HF, potentially clarifying 'wet' BNP levels.
Objective:
To assess serum levels of tumor marker carbohydrate antigen 125 (CA125) in patients with heart failure (HF) and to investigate possible correlation with echocardiographic parameters and level of brain natriuretic peptide (BNP).
Patients And Methods:
We included 76 patients with different cardiac symptoms hospitalized at Clinic for heart disease and rheumatism. Control group (n = 26) was consisted of patients without signs and symptoms of HF, normal left ventricle ejection fraction (LVEF) and normal BNP level. Patients with diagnosis of HF (n = 50) were subdivided into 2 group depending on signs and symptoms of fluid overload: compensated (compHF, n = 10) and decompensated group (decompHF, n = 40). Serum CA125 and BNP were measured on admission and all patient underwent ECG recording and trans thoracic echocardiographic examination.
Results:
The median CA125 level in HF group was significantly higher compared to control group (71.05 [30.70-141.47]U/ml vs 10.75 [8.05- 14.32] U/ml, p < 0.0005). Higher CA125 levels were found in decompHF group compared to compHF group (94.90 [49.75-196.75]U/ml vs 11.90 [10.25-15.80]U/ml, p < 0.0005). In decompHF group 13 of patients had pleural and/or pericardial effusion- their CA125 levels were significantly higher compared to patients without serosal effusion (n = 27) (205.10 [106.50-383.90]U/ml vs. 71.50 [47.30-109.55] U/ml, p < 0.002). We found significant difference in CA125 levels between patients with atrial fibrillation and sinus rhythm (98.40 [48.20-242.70] U/ml vs. 47.30 [12.95-99.05] U/ml, p = 0.015). There was no significant difference in CA125 levels in group with enlarged left atrium compared to normal sized atrium (p = 0.282), as well as in group with moderate/severe mitral regurgitation compared to group with no/mild mitral regurgitation (p = 0.99). Finally, levels of serum CA125 positively correlated with serum level of BNP (r = 0.293, p = 0.039), but not with LVEF (p = 0.369) and left atrium diameter (p = 0.636).
Conclusion:
Serum CA125 is elevated in decompensated HF patients: more pronounced elevation was found in patients with pleural and/or pericard effusion compared to patients with no serosal effusion. CA125 level correlated with BNP, but not with left atrium diameter nor with LVEF. Tumor marker CA125 could be used as a marker of systemic congestion and volume overload in decompensated HF. We hypothesized that high CA125 level indicates that measured high BNP is actually wet BNP.
More Related Videos
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure III: Clinical Manifestations
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy

